Acasti Stock Today

ACST Stock  CAD 0.92  0.06  6.98%   
Market Performance
7 of 100
Odds Of Distress
Less than 50
Acasti Pharma is selling for under 0.92 as of the 6th of February 2023; that is 6.98 percent increase since the beginning of the trading day. The stock's lowest day price was 0.92. Acasti Pharma has 50 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Acasti Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 12th of April 2022 and ending today, the 6th of February 2023. Click here to learn more.
Fiscal Year End
March
Category
Healthcare
ISIN
CA00430K8730
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. The company was incorporated in 2002 and is headquartered in Laval, Canada. ACASTI PHARMA is traded on Commodity Exchange in Exotistan.. The company has 44.61 M outstanding shares of which 20.68 K shares are presently shorted by private and institutional investors with about 2.25 days to cover all short positions. More on Acasti Pharma

Acasti Pharma Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Acasti Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Acasti Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEOJanelle DAlvise
Macroaxis Advice
The buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Acasti Pharma's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellOvervalued
Acasti Pharma (ACST) is traded on TSX Venture Exchange in Canada and employs 16 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.04 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acasti Pharma's market, we take the total number of its shares issued and multiply it by Acasti Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Acasti Pharma operates under Healthcare sector and is part of Biotechnology industry. The entity has 44.61 M outstanding shares of which 20.68 K shares are presently shorted by private and institutional investors with about 2.25 days to cover all short positions. Acasti Pharma has accumulated about 57.72 M in cash with (17.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Acasti Pharma Probability Of Bankruptcy
Ownership
Acasti Pharma holds a total of fourty-four million six hundred twelve thousand eight hundred outstanding shares. Acasti Pharma retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Allocation

Check Acasti Ownership Details

Acasti Stock Price Odds Analysis

Depending on a normal probability distribution, the odds of Acasti Pharma jumping above the current price in 90 days from now is about 15.87%. The Acasti Pharma probability density function shows the probability of Acasti Pharma stock to fall within a particular range of prices over 90 days. Assuming the 90 days trading horizon Acasti Pharma has a beta of -0.8845. This suggests Additionally, the company has an alpha of 0.5596, implying that it can generate a 0.56 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 0.92HorizonTargetOdds Above 0.92
84.08%90 days
 0.92 
15.87%
Based on a normal probability distribution, the odds of Acasti Pharma to move above the current price in 90 days from now is about 15.87 (This Acasti Pharma probability density function shows the probability of Acasti Stock to fall within a particular range of prices over 90 days) .

Acasti Pharma Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Acasti Pharma market risk premium is the additional return an investor will receive from holding Acasti Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Acasti Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Acasti Pharma's alpha and beta are two of the key measurements used to evaluate Acasti Pharma's performance over the market, the standard measures of volatility play an important role as well.

Acasti Stock Against Markets

Picking the right benchmark for Acasti Pharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Acasti Pharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Acasti Pharma is critical whether you are bullish or bearish towards Acasti Pharma at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Acasti Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module

Acasti Pharma Corporate Executives

Elected by the shareholders, the Acasti Pharma's board of directors comprises two types of representatives: Acasti Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acasti. The board's role is to monitor Acasti Pharma's management team and ensure that shareholders' interests are well served. Acasti Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acasti Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Linda OKeefe - Chief Financial OfficerProfile
Brian Ford - Chief Financial OfficerProfile
Pierre Lemieux - Chief Operating OfficerProfile

Invested in Acasti Pharma?

The danger of trading Acasti Pharma is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Acasti Pharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Acasti Pharma. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Acasti Pharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for analysis

When running Acasti Pharma price analysis, check to measure Acasti Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acasti Pharma is operating at the current time. Most of Acasti Pharma's value examination focuses on studying past and present price action to predict the probability of Acasti Pharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acasti Pharma's price. Additionally, you may evaluate how the addition of Acasti Pharma to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Global Correlations
Find global opportunities by holding instruments from different markets
Bond Directory
Find actively traded corporate debentures issued by US companies
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Please note, there is a significant difference between Acasti Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Acasti Pharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acasti Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.